Year: 2026
Type: article
Abstract: Endometriosis is a chronic, inflammatory, estrogen-dependent gynecological disease that affects approximately 10% of women of reproductive age and is a major cause of chronic pelvic pain, infertility, and reduced quality of life.Although conventional treatments are based primarily on hormonal therapies and surgical approaches, many cases present with symptom recurrence or therapeutic limitations.Recently, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists-widely used in the treatment of obesity and type 2 diabetes mellitus-have attracted interest due to their anti-inflammatory, immunomodulatory, and metabolic effects.The present study aims to discuss the potential mechanisms by which GLP-1 and GIP agonists may represent a new therapeutic strategy for endometriosis.This is a narrative review of the literature based on recent publications regarding the pathophysiology of endometriosis, systemic inflammation, insulin resistance, obesity, and the actions of incretin mimetics.The findings suggest that these medications may help reduce the inflammatory process, modulate the immune response, control metabolism, and slow the progression of endometriotic lesions.Although clinical evidence is still limited, preliminary results point to a promising area of research that could expand the therapeutic options available to patients with endometriosis.
Source: Open Minds International Journal
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7214937049
